Eliem Therapeutics Inc - ESG Rating & Company Profile powered by AI
The ESG assessment for Eliem Therapeutics Inc represents the company's transparency towards the UN Sustainable Development Goals. Alternative corporations in the rating peer group for Eliem Therapeutics Inc are displayedin the table. This page is a zero-cost Sustainability analysis for Eliem Therapeutics Inc.
Eliem Therapeutics Inc in the Biotechnology & Medical Research industry gained a UN SDG ESG Transparency Score of 6.7; made up of an environmental score of 8.0, social score of 4.0 and governance score of 8.0.
6.7
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Analytik Jena AG | 8.0 | High |
| 1 | Amniotics AB (publ) | 8.0 | High |
| 31 | Precipio Inc | 6.9 | High |
| 33 | FYI Resources Ltd | 6.8 | High |
| 34 | Eliem Therapeutics Inc | 6.7 | High |
| 34 | Ncardia AG | 6.7 | High |
| 34 | Mainstay Medical International PLC | 6.7 | High |
| ... | ... | ... | |
| 182 | Wesana Health Holdings Inc | 0.0 | Low |
| 182 | rEVO Biologics Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Eliem Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Eliem Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Eliem Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Eliem Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Eliem Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Eliem Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Eliem Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Eliem Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Eliem Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Eliem Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Eliem Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Eliem Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Eliem Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Eliem Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Eliem Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Eliem Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Eliem Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Eliem Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Eliem Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Eliem Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Eliem Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Eliem Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Eliem Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Eliem Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Eliem Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Eliem Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Eliem Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Eliem Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Eliem Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Eliem Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Eliem Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Eliem Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Eliem Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Eliem Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Eliem Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Eliem Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Eliem Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.